
==== Front
BMC Nephrol
BMC Nephrol
BMC Nephrology
1471-2369
BioMed Central London

39272061
3753
10.1186/s12882-024-03753-1
Research
Association of chronic kidney disease with postoperative outcomes: a national surgical quality improvement program (NSQIP) multi-specialty surgical cohort analysis
Riveros Carlos 1
Ranganathan Sanjana 1
Shah Yash B. 2
Huang Emily 1
Xu Jiaqiong 3
Hsu Enshuo 3
Geng Michael 4
Hu Siqi 1
Melchiode Zachary 1
Miles Brian J. 1
Esnaola Nestor 5
Klaassen Zachary 6
Jerath Angela 7
Wallis Christopher J.D. 8910
Satkunasivam Raj raj.satkunasivam@gmail.com

1
1 https://ror.org/027zt9171 grid.63368.38 0000 0004 0445 0041 Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX 77030 USA
2 https://ror.org/00ysqcn41 grid.265008.9 0000 0001 2166 5843 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA USA
3 https://ror.org/027zt9171 grid.63368.38 0000 0004 0445 0041 Center for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, TX USA
4 https://ror.org/01f5ytq51 grid.264756.4 0000 0004 4687 2082 School of Engineering Medicine, Texas A&M University, Houston, TX USA
5 https://ror.org/027zt9171 grid.63368.38 0000 0004 0445 0041 Department of Surgery, Houston Methodist Hospital, Houston, TX USA
6 https://ror.org/012mef835 grid.410427.4 0000 0001 2284 9329 Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA USA
7 https://ror.org/03wefcv03 grid.413104.3 0000 0000 9743 1587 Department of Anesthesia, Sunnybrook Health Sciences Center, Toronto, ON Canada
8 grid.17063.33 0000 0001 2157 2938 Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON Canada
9 https://ror.org/03dbr7087 grid.17063.33 0000 0001 2157 2938 Division of Urology, University of Toronto, Toronto, ON Canada
10 https://ror.org/05deks119 grid.416166.2 0000 0004 0473 9881 Division of Urology, Mount Sinai Hospital, Toronto, ON Canada
13 9 2024
13 9 2024
2024
25 3057 8 2023
10 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Chronic kidney disease (CKD) is associated with higher incidence of major surgery. No studies have evaluated the association between preoperative kidney function and postoperative outcomes across a wide spectrum of procedures. We aimed to evaluate the association between CKD and 30-day postoperative outcomes across surgical specialties.

Methods

We selected adult patients undergoing surgery across eight specialties. The primary study endpoint was major complications, defined as death, unplanned reoperation, cardiac complication, or stroke within 30 days following surgery. Secondary outcomes included Clavien-Dindo high-grade complications, as well as cardiac, pulmonary, infectious, and thromboembolic complications. Multivariable regression was performed to evaluate the association between CKD and 30-day postoperative complications, adjusted for baseline characteristics, surgical specialty, and operative time.

Results

In total, 1,912,682 patients were included. The odds of major complications (adjusted odds ratio [aOR] 2.14 [95% confidence interval (CI): 2.07, 2.21]), death (aOR 3.03 [95% CI: 2.88, 3.19]), unplanned reoperation (aOR 1.57 [95% CI: 1.51, 1.64]), cardiac complication (aOR 3.51 [95% CI: 3.25, 3.80]), and stroke (aOR 1.89 [95% CI: 1.64, 2.17]) were greater for patients with CKD stage 5 vs. stage 1. A similar pattern was observed for the secondary endpoints.

Conclusion

This population-based study demonstrates the negative impact of CKD on operative outcomes across a diverse range of procedures and patients.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12882-024-03753-1.

Keywords

Chronic kidney disease
Postoperative outcomes
Quality improvement
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Glomerular filtration rate (GFR), whether estimated or indirectly measured, is a widely accepted marker of overall renal function [1]. Decreased kidney function for at least 3 months, as indicated by GFR < 60 ml/min/1.73m2 and/or the presence of kidney damage markers, characterizes chronic kidney disease (CKD) [2]. The prevalence of CKD is almost 11% in high-income nations and is the fourteenth leading cause of death worldwide, hence posing a public health challenge [3]. Further, CKD is a well-recognized independent predictor of cardiovascular events, hospitalizations, and all-cause mortality [4, 5].

Chronic kidney disease has been previously demonstrated to influence surgical outcomes, with patients experiencing increased length of stay and requiring intensive postoperative management [6–9]. Harrison et al. previously reported that CKD is not only associated with a higher incidence of major surgery [10], but also greater odds of death and myocardial infarction following ambulatory non-cardiac operations [11]. However, no studies have evaluated the association between preoperative kidney function and postoperative outcomes across a wide spectrum of common surgical procedures. We postulated that CKD may be independently associated with worse 30-day outcomes following surgery, and that there would be significant variation among specialties. To test this hypothesis, we performed a population-based retrospective cohort study of surgical patients, evaluating the association between CKD and 30-day postoperative outcomes across various specialties.

Materials and methods

Study design and population

This retrospective study utilized data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Briefly, the ACS-NSQIP is a validated database of prospectively collected 30-day perioperative data from over 600 participating community and academic institutions [12]. This study was deemed exempt by our institutional review board as the ACS-NSQIP contains de-identified data. This study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline and the Reporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) statement [13, 14].

Cohort selection

We selected patients aged ≥ 18 years undergoing elective surgery across any of the following eight specialties: gynecology, orthopedics, urology, thoracic, cardiac, general, vascular, and neurosurgery between 2005 and 2021. Using Common Procedural Terminology (CPT) codes (Supplementary Table 1), we identified a representative multiprocedural cohort. Patients with missing age, sex, race, height, weight, preoperative laboratory values, American Society of Anesthesiologists (ASA) physical status class, functional health status, or operative time were excluded.

Outcomes

The primary study endpoint was major complication, defined as death, unplanned reoperation, cardiac complication (myocardial infarction, cardiac arrest requiring cardiopulmonary resuscitation), and stroke within 30 days following surgery [15]. Secondary outcomes included Clavien-Dindo high-grade complication (defined as death, unplanned reoperation, septic shock, pulmonary embolism, cardiac complication, stroke, reintubation, prolonged intubation, coma, or acute renal failure), as well as cardiac, pulmonary (reintubation or prolonged intubation), infectious (pneumonia, urinary tract infection, wound infection, or sepsis), and thromboembolic (deep venous thrombosis or pulmonary embolism) complications.

Exposure and covariates

We calculated estimated GFR, using serum creatinine adjusted for age and sex, with the recommended race-agnostic CKD-EPI Eqs [16, 17]. Estimated GFR was categorized according to the Kidney Disease Improving Global Outcomes CKD 2012 Guidelines, with stage 1: ≥90 mL/min/1.73m2; 2: 60–89 mL/min/1.73m2; 3a: 45–59 mL/min/1.73m2; 3b: 30–44 mL/min/1.73m2; 4: 15–29 mL/min/1.73m2; and 5: <15 mL/min/1.73m2 [2]. The upper bound of age at surgery was capped at 90 years. Body mass index (BMI) was calculated using height and weight, and patients were categorized into underweight, normal, overweight, or obese according to the Centers for Disease Control classification [18].

American Society of Anesthesiologists status, smoking history (within 1 year prior to surgery), steroid use for chronic conditions, functional health status, chronic obstructive pulmonary disease (COPD), diabetes mellitus requiring therapy (oral or insulin), as well as cardiac (congestive heart failure in 30 days before surgery, history of myocardial infarction 6 months prior to surgery, previous cardiac surgery, history of angina 1 month before surgery, or arterial hypertension requiring medication), and neurologic history (transient ischemic attack, stroke, hemiplegia, or quadriplegia) were reported. We reported surgical specialty, preoperative hematocrit and platelet count, as well as operative time and perioperative transfusion of ≥ 1 unit of packed or whole red blood cells.

Statistical analysis

We presented the preoperative characteristics and 30-day postoperative complication rates of all patients, stratified by CKD stage. All data were presented as mean ± standard deviation (SD) for continuous variables, and number (%) for categorical variables. To account for the ordinal nature of CKD stages, we analyzed the trend of each preoperative characteristics and outcomes across CKD stages using the Cochran-Armitage test and ordinal logistic regression analysis for binary and ordinal categorical variables, respectively, and linear regression analysis for continuous variables. We characterized the preoperative profile of patients who experienced 30-day complications, stratified by CKD stage. Multivariable logistic regression analysis was performed for the primary endpoint and its components, as well as the secondary endpoints. Chronic kidney disease stage 1 was used as the reference category. We evaluated the association between CKD and 30-day postoperative complications, adjusted for age, race, BMI, ASA category, cardiac and neurologic history, COPD, diabetes, 12-month smoking status, steroid use for chronic conditions, functional health status, preoperative hematocrit and platelet counts, perioperative transfusion, operative time, and surgical specialty. The models’ predictive margins of CKD stages were estimated and visualized with forest plots. Stratified modeling further examined the association of CKD stages with our primary endpoint, by specialty subgroups. Further, we performed a post-hoc sensitivity analysis by excluding urologic procedures that inherently impact postoperative renal function (i.e. nephrectomy). All tests were two-tailed and p ≤ 0.05 was deemed significant. All analyses were performed with STATA 16.1 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC). Figures were graphed using GraphPad Prism (GraphPad Software LLC, version 9.0, San Diego, CA, USA).

Results

Variation in baseline characteristics by CKD stage

In total, 1,912,682 patients were included in this analysis (Fig. 1). This cohort was stratified by CKD stage, with 861,721 patients with CKD Stage 1, 752,508 with Stage 2, 167,902 with Stage 3a, 73,616 with Stage 3b, 30,649 with Stage 4, and 26,286 with Stage 5 (Table 1). In terms of demographics, patients with advanced stage CKD tended to be older and underweight (both p for trend < 0.001). These patients demonstrated increased rates of various comorbidities, including a poorer ASA status and increased history of cardiac and neurologic events, COPD, diabetes, tobacco use, and chronic steroid utilization (all p for trend < 0.001). Preoperative platelet counts and hematocrit decreased with advanced CKD stage (both p for trend < 0.001) as well. Overall, functional status was markedly lower in those with worse CKD staging (p for trend < 0.001). Surgery type, as measured by surgical specialty, was markedly different based on CKD staging. Most notably, patients of advanced CKD stage were less likely to undergo gynecologic and orthopedic procedures, but significantly more likely to undergo urologic and vascular operations (p for trend < 0.001).

Fig. 1 Patient selection flow diagram

Table 1 Preoperative characteristics

	Total	CKD Categories	P for trend4	
1	2	3a	3b	4	5	
N = 1,912,682	N = 861,721	N = 752,508	N = 167,902	N = 73,616	N = 30,649	N = 26,286	
Age1	61.8 ± 13.9	55.3 ± 13.3	65.6 ± 12.0	71.3 ± 10.4	72.8 ± 10.9	70.2 ± 12.4	63.8 ± 12.7	< 0.001	
 18–50	365,135 (19.1)	280,595 (32.6)	71,711 (9.5)	5,089 (3.0)	2,307 (3.1)	1,925 (6.3)	3,508 (13.3)		
 50–70	949,769 (49.7)	455,522 (52.9)	385,578 (51.2)	60,598 (36.1)	22,904 (31.1)	11,413 (37.2)	13,754 (52.3)		
 70+	597,778 (31.3)	125,604 (14.6)	295,219 (39.2)	102,215 (60.9)	48,405 (65.8)	17,311 (56.5)	9,024 (34.3)		
Female Sex	1,131,724 (59.2)	517,262 (60.0)	444,849 (59.1)	98,960 (58.9)	42,932 (58.3)	16,001 (52.2)	11,720 (44.6)	< 0.001	
Race/Ethnicity2								< 0.001	
 White	1,483,893 (77.6)	654,337 (75.9)	605,432 (80.5)	133,143 (79.3)	56,810 (77.2)	21,436 (69.9)	12,735 (48.4)	< 0.001	
 Black	215,302 (11.3)	81,611 (9.5)	84,831 (11.3)	22,297 (13.3)	11,089 (15.1)	6,001 (19.6)	9,473 (36.0)	< 0.001	
 Hispanic	139,182 (7.3)	85,135 (9.9)	38,282 (5.1)	7,450 (4.4)	3,512 (4.8)	2,134 (7.0)	2,669 (10.2)	< 0.001	
 Other	74,305 (3.9)	40,638 (4.7)	23,963 (3.2)	5,012 (3.0)	2,205 (3.0)	1,078 (3.5)	1,409 (5.4)	< 0.001	
BMI3	31.0 ± 8.1	31.2 ± 8.6	31.0 ± 7.6	30.8 ± 7.5	30.4 ± 7.7	29.7 ± 8.1	29.3 ± 7.9	< 0.001	
 Underweight	33,992 (1.8)	18,365 (2.1)	9,546 (1.3)	2,687 (1.6)	1,541 (2.1)	1,020 (3.3)	833 (3.2)		
 Normal	407,445 (21.3)	193,205 (22.4)	148,843 (19.8)	33,317 (19.8)	16,395 (22.3)	8,277 (27.0)	7,408 (28.2)		
 Overweight	557,646 (29.2)	236,415 (27.4)	230,780 (30.7)	51,720 (30.8)	22,141 (30.1)	8,786 (28.7)	7,804 (29.7)		
 Obese	913,599 (47.8)	413,736 (48.0)	363,339 (48.3)	80,178 (47.8)	33,539 (45.6)	12,566 (41.0)	10,241 (39.0)		
ASA Classification								< 0.001	
 1-No Disturbance	39,803 (2.1)	26,430 (3.1)	12,592 (1.7)	604 (0.4)	110 (0.1)	32 (0.1)	35 (0.1)		
 2-Mild Disturbance	748,915 (39.2)	398,615 (46.3)	299,378 (39.8)	39,292 (23.4)	9,461 (12.9)	1,434 (4.7)	735 (2.8)		
 3-Severe Disturbance	960,671 (50.2)	393,143 (45.6)	389,198 (51.7)	105,581 (62.9)	46,945 (63.8)	15,224 (49.7)	10,580 (40.2)		
 4-Life Threatening Disturbance	156,240 (8.2)	42,316 (4.9)	49,826 (6.6)	21,422 (12.8)	15,930 (21.6)	12,544 (40.9)	14,202 (54.0)		
 5-Moribund	7,053 (0.4)	1,217 (0.1)	1,514 (0.2)	1,003 (0.6)	1,170 (1.6)	1,415 (4.6)	734 (2.8)		
Cardiac History	66,974 (3.5)	15,042 (1.7)	23,923 (3.2)	10,874 (6.5)	7,580 (10.3)	5,079 (16.6)	4,476 (17.0)	< 0.001	
Neurologic History	23,582 (1.2)	5,973 (0.7)	8,499 (1.1)	3,773 (2.2)	2,429 (3.3)	1,465 (4.8)	1,443 (5.5)	< 0.001	
History of Severe COPD	104,182 (5.4)	35,181 (4.1)	40,965 (5.4)	13,799 (8.2)	7,625 (10.4)	3,833 (12.5)	2,779 (10.6)	< 0.001	
Diabetes Mellitus Requiring Therapy	369,051 (19.3)	135,383 (15.7)	134,742 (17.9)	46,896 (27.9)	26,184 (35.6)	13,070 (42.6)	12,776 (48.6)	< 0.001	
Current Smoker within One Year	315,955 (16.5)	173,421 (20.1)	101,288 (13.5)	21,545 (12.8)	9,969 (13.5)	5,130 (16.7)	4,602 (17.5)	< 0.001	
Steroid Use for a Chronic Condition	90,840 (4.7)	40,397 (4.7)	30,344 (4.0)	9,395 (5.6)	5,454 (7.4)	3,190 (10.4)	2,060 (7.8)	< 0.001	
Functional Health Status								< 0.001	
 Independent	1,838,161 (96.1)	839,839 (97.5)	729,761 (97.0)	158,220 (94.2)	65,951 (89.6)	24,384 (79.6)	20,006 (76.1)		
 Partially Dependent	58,887 (3.1)	16,946 (2.0)	19,012 (2.5)	7,950 (4.7)	5,873 (8.0)	4,282 (14.0)	4,824 (18.4)		
 Totally Dependent	15,634 (0.8)	4,936 (0.6)	3,735 (0.5)	1,732 (1.0)	1,792 (2.4)	1,983 (6.5)	1,456 (5.5)		
Surgical Specialty									
 Cardiac Surgery	29,565 (1.5)	9,745 (1.1)	12,844 (1.7)	3,859 (2.3)	1,714 (2.3)	657 (2.1)	746 (2.8)	< 0.001	
 General Surgery	704,115 (36.8)	354,797 (41.2)	245,371 (32.6)	53,863 (32.1)	27,364 (37.2)	14,411 (47.0)	8,309 (31.6)	< 0.001	
 Gynecology	237,840 (12.4)	145,363 (16.9)	79,183 (10.5)	9,295 (5.5)	2,756 (3.7)	684 (2.2)	559 (2.1)	< 0.001	
 Neurosurgery	9,516 (0.5)	4,522 (0.5)	3,222 (0.4)	852 (0.5)	437 (0.6)	228 (0.7)	255 (1.0)	< 0.001	
 Orthopedic Surgery	677,404 (35.4)	267,391 (31.0)	317,375 (42.2)	65,276 (38.9)	21,492 (29.2)	4,182 (13.6)	1,688 (6.4)	< 0.001	
 Thoracic Surgery	35,228 (1.8)	14,189 (1.6)	15,746 (2.1)	3,569 (2.1)	1,253 (1.7)	302 (1.0)	169 (0.6)	< 0.001	
 Urology	62,545 (3.3)	17,859 (2.1)	25,496 (3.4)	9,634 (5.7)	4,793 (6.5)	1,756 (5.7)	3,007 (11.4)	< 0.001	
 Vascular Surgery	156,469 (8.2)	47,855 (5.6)	53,271 (7.1)	21,554 (12.8)	13,807 (18.8)	8,429 (27.5)	11,553 (44.0)	< 0.001	
Preoperative Hematocrit	39.3 ± 5.4	39.6 ± 5.1	40.0 ± 5.1	38.2 ± 5.6	36.2 ± 6.0	33.7 ± 6.5	32.5 ± 6.0	< 0.001	
Preoperative Platelet Count	260.4 ± 87.7	269.2 ± 90.0	254.6 ± 80.9	250.8 ± 87.5	251.1 ± 97.3	248.0 ± 111.3	241.7 ± 107.3	< 0.001	
Transfusion of ≥ 1 Unit of RBCs	25,919 (1.4)	9,058 (1.1)	6,771 (0.9)	2,991 (1.8)	2,503 (3.4)	2,453 (8.0)	2,143 (8.2)	< 0.001	
CKD: chronic kidney disease; BMI: body mass index; COPD: chronic obstructive pulmonary disease; RBCs: red blood cells

1. Age at surgery in years. Patients < 18 years old are not included in dataset; ≥ 90 years old were converted to 90

2. Race and ethnicity were merged into a single variable

3. BMI is categorized using the CDC’s classification: underweight, normal, overweight, and obese

4. Linear regression analysis was used to determine the relationship between CKD (eGFR) and continuous variables; the Cochran-Armitage test for trend was used to examine trends across the categories of CKD for categorical variables

Association between postoperative complication rates and CKD stage

Unadjusted postoperative complication rates were significantly increased across patients with advanced CKD staging. Major complications, namely death, unplanned reoperation, cardiac complication and stroke were all significantly more frequent among patients with advanced stage CKD (all p < 0.001). Most notably, while only 1.8% of the total cohort died within 30 days, 12.2% of patients with end stage renal disease (CKD 5) died within the same period. Similarly, reoperations occurred in 13% of patients with CKD 5, compared to 4.2% among the general cohort (Table 2). Regarding secondary endpoints, rates were significantly higher in patients with advanced CKD (4 & 5). Specifically, Clavien-Dindo high-grade complications, bleeding, pulmonary, infectious, and thromboembolic complications were all more common as CKD stage increased (p for trend < 0.001).

Table 2 Postoperative outcomes

	Total	CKD Categories	P for trend	
1	2	3a	3b	4	5	
Outcomes	N = 1,912,682	N = 861,721	N = 752,508	N = 167,902	N = 73,616	N = 30,649	N = 26,286	
Major complication	112,847 (5.9)	39,224 (4.6)	36,174 (4.8)	13,289 (7.9)	9,891 (13.4)	7,801 (25.5)	6,468 (24.6)	< 0.001	
 Death	33,829 (1.8)	7,038 (0.8)	9,124 (1.2)	4,879 (2.9)	4,793 (6.5)	4,776 (15.6)	3,219 (12.2)	< 0.001	
 Unplanned reoperation	79,995 (4.2)	32,316 (3.8)	27,069 (3.6)	8,491 (5.1)	5,326 (7.2)	3,374 (11.0)	3,419 (13.0)	< 0.001	
 Cardiac complication	11,149 (0.6)	2,496 (0.3)	3,257 (0.4)	1,596 (1.0)	1,343 (1.8)	1,232 (4.0)	1,225 (4.7)	< 0.001	
 Stroke	5,176 (0.3)	1,321 (0.2)	1,845 (0.2)	811 (0.5)	569 (0.8)	353 (1.2)	277 (1.1)	< 0.001	
Clavien-Dindo high grade complications	155,591 (8.1)	51,277 (6.0)	48,371 (6.4)	18,581 (11.1)	14,217 (19.3)	12,352 (40.3)	10,793 (41.1)	< 0.001	
Pulmonary complication	52,933 (2.8)	14,679 (1.7)	15,064 (2.0)	7,279 (4.3)	6,425 (8.7)	5,752 (18.8)	3,734 (14.2)	< 0.001	
Infectious complication	262,642 (13.7)	109,354 (12.7)	84,745 (11.3)	27,444 (16.3)	18,321 (24.9)	12,689 (41.4)	10,089 (38.4)	< 0.001	
 Sepsis	153,269 (8.0)	59,947 (7.0)	44,789 (6.0)	16,939 (10.1)	12,927 (17.6)	10,287 (33.6)	8,380 (31.9)	< 0.001	
 Pneumonia	37,921 (2.0)	12,616 (1.5)	12,199 (1.6)	4,940 (2.9)	3,724 (5.1)	2,740 (8.9)	1,702 (6.5)	< 0.001	
 Urinary tract infection	36,477 (1.9)	14,789 (1.7)	13,608 (1.8)	4,069 (2.4)	2,338 (3.2)	1,139 (3.7)	534 (2.0)	< 0.001	
 Wound infection	110,437 (5.8)	52,435 (6.1)	37,512 (5.0)	9,725 (5.8)	5,424 (7.4)	2,941 (9.6)	2,400 (9.1)	< 0.001	
Venous thromboembolism	27,471 (1.4)	10,861 (1.3)	10,307 (1.4)	3,034 (1.8)	1,756 (2.4)	926 (3.0)	587 (2.2)	< 0.001	
 Deep venous thrombosis	19,704 (1.0)	7,683 (0.9)	7,135 (0.9)	2,201 (1.3)	1,415 (1.9)	778 (2.5)	492 (1.9)	< 0.001	
 Pulmonary embolism	10,149 (0.5)	4,131 (0.5)	4,158 (0.6)	1,090 (0.6)	460 (0.6)	185 (0.6)	125 (0.5)	< 0.001	
Bleeding	174,796 (9.1)	60,932 (7.1)	59,393 (7.9)	22,740 (13.5)	15,218 (20.7)	9,289 (30.3)	7,224 (27.5)	< 0.001	
Acute renal failure	18,703 (1.0)	2,012 (0.2)	2,915 (0.4)	1,865 (1.1)	2,233 (3.0)	4,576 (14.9)	5,102 (19.4)	< 0.001	
1. All outcomes are dichotomous. There is no missing data

2. Cochran-Armitage test for trend was used to examine trends across the categories of CKD for all outcome variables

Predictive value of CKD for postoperative outcomes

After multivariable logistic regression, the odds of most complications were associated with increasing CKD stage (Figs. 2 and 3). In general, the odds of each complication type increased proportionally with CKD staging. Specifically, the odds of major complications were more than double for CKD stage 5 patients (adjusted odds ratio [aOR] 2.14 [95% confidence interval (CI): 2.07, 2.21]), while odds of death were tripled (aOR 3.03 [95% CI: 2.88, 3.19]), when compared to patients with CKD stage 1. Reoperations were 57% more likely among patients with CKD stage 5 (aOR 1.57 [95% CI :1.51, 1.64]) compared to stage 1. Within the components of the primary outcome, the magnitude of odds was greatest for cardiac complications (CKD stage 5: aOR 3.51 [95% CI: 3.25, 3.80]). Chronic kidney disease stage 4 and 5 were both associated with greater odds of stroke (aOR 1.96 [95% CI: 1.72, 2.23] and aOR 1.89 [95% CI: 1.64, 2.17], respectively), compared to CKD stage 1.

The odds of secondary outcomes for patients with CKD stage 5 were each substantially increased as well. Increasing CKD stage was associated with greater odds of bleeding requiring transfusion (CKD stage 4: aOR 1.81 [95% CI: 1.76, 1.87] and CKD stage 5: aOR 1.19 [95% CI: 1.15, 1.23]). Of note, the risk of a VTE was significantly increased with CKD stages 3a, 3b, and 4, but not stage 5. Subgroup analysis of major complications revealed consistency of results for most specialties, namely cardiac and general surgery, neurosurgery, orthopedics, and urology (Fig. 4). There were notable differences for gynecology, thoracic, and vascular surgery. There was no association between CKD stage 5 and major complications for gynecology. For thoracic and vascular surgery, there was no association between CKD stage 3 and major complications. In sensitivity analysis, overall results remained unchanged for primary and secondary endpoints, after exclusion of CPT codes for nephrectomy (Supplementary Fig. 1). In further subgroup analysis, there was a decrease in the magnitude of the associations between increasing CKD stages and major complications (Supplementary Fig. 2). The only exception was urology, in which there was no longer an association between CKD stage 3 and major complications.

Fig. 2 Association between CKD stage and major complications (along with its components) after multivariable analysis. CKD Stage 1 is the reference category. CKD: chronic kidney disease; aOR: adjusted odds ratio; CI: confidence interval

Discussion

This population-based analysis of more than 1.9 million patients provides a comprehensive overview of the effects of CKD on postoperative outcomes, both corroborating previous literature and adding novel insights into the understanding of the importance of CKD. Though it may seem predictable that common patient comorbidities such as CKD can worsen outcomes, this study includes a rigorous statistical analysis, adjusting for numerous confounders, to provide quantifiable risk which can be used to counsel patients on clinical decision-making. Further, this study suggests that CKD is associated with greater odds of nearly all key postoperative adverse outcomes, including cardiovascular events, stroke, pulmonary complications, infectious, and bleeding events. Results remained robust after subgroup and sensitivity analyses.

Fig. 3 Association between CKD stage and secondary endpoints after multivariable analysis. CKD Stage 1 is the reference category. CKD: chronic kidney disease; CDHG: Clavien-Dindo high-grade; VTE: venous thromboembolism; aOR: adjusted odds ratio; CI: confidence interval

Previous studies have not evaluated the association between CKD and postoperative outcomes within a diverse multi-specialty surgical cohort and have instead been limited to specific procedures within surgical specialties, thus limiting generalizability. The association of CKD with complications following major abdominal surgery was previously investigated, with a 29% increase in complications and a sevenfold increase in mortality in hemodialysis patients [6]. Infections were found to be the predominant complication. Similarly, patients with stage 5 CKD undergoing bariatric surgery were found to have nearly doubled risk of readmission and increased length of stay, along with infections and mortality. However, the authors suggest that bariatric surgery could be renoprotective overall, and the absolute rates of complications, while relatively higher, remained low in terms of absolute values [19]. Similarly, with regard to cardiac surgery, CKD has been shown as an independent risk factor of major complications and mortality following aortic repair [20]. Studies have gone as far as finding that simultaneous kidney transplantation may benefit heart transplant outcomes in patients with baseline CKD [21]. CKD in vascular surgery patients has been shown to increase mortality, cardiovascular and cerebrovascular events, bleeds, and AKI along with reduced chances of procedural success [22–24].

Orthopedic surgery has similarly shown increased general morbidity, as a single institution study of lumbar arthrodesis patients found increase rates of intensive care unit transfer, delirium, urinary tract infection, and deep vein thrombosis in CKD patients, along with an increase in readmissions although this was not statistically significant [25]. Total hip arthroplasty has also been shown to yield poorer outcomes with hemodialysis, with threefold increased mortality, 50% increased emergency room visits, and 2.7 times increased readmissions, although infection or revision rates were not increased [26]. Overall, the authors remarked that CKD may not increase orthopedic implant-related complications, but general medical morbidity was significantly poorer. In a separate study of diabetic patients receiving humerus fracture fixation surgery, CKD patients were shown to have increased revision, infection, readmission, and mortality risk [27]. Finally, transmetatarsal amputation failure is 100% more likely in CKD patients, while conferring a 182% increased mortality risk [28]. Otolaryngology has paralleled these findings, demonstrating that readmissions occur at fivefold increased rates following parathyroidectomy in CKD patients [29]. Similarly, urology has demonstrated the effects of CKD on nephrectomy outcomes, with one study demonstrating the value of incorporating baseline CKD into a metric predicting postoperative outcomes [30]. There does not appear to be any previous study of the effects of CKD on gynecologic surgery outcomes.

Fig. 4 Association between CKD stage and major complications, subgrouped by surgical specialty. CKD Stage 1 is the reference category. aOR: adjusted odds ratio; CI: confidence interval

Interestingly, the predictivity of CKD staging for several complications categories, including pulmonary, infectious, thromboembolic, and bleeding events, appeared to slightly decrease between CKD stage 4 to 5, although it still remained significantly greater than that for lower stage CKD patients. One study limited to bariatric surgery patients interestingly found that although increasing CKD stage was associated with postoperative mortality, this effect appeared to be mitigated with stage 4 and 5 CKD [19]. CKD has been classically associated with an increased risk of bleeding, but also a paradoxical thrombotic potential. This is thought to be secondary to delayed clot formation yet increased clot strength and decreased breakdown [31]. Although we found advanced CKD to be associated with an increased risk of bleeding across all stages of CKD, we did not find a similar uniform association for VTE. We believe this finding is due to the higher rates of DVT but not PE among patients with CKD. Large population-based observational studies have found that patients with advanced CKD have greater odds of VTE at 1 year (HR 1.83, 95% CI 1.03–3.25) but not at 30-days (HR 1.64 [95% CI: 0.59, 4.54]) [32]. This could also explain why we failed to show a consistent association between 30-day postoperative VTE and all stages of CKD.

Although NSQIP is a validated database with strict quality control measures, this study has limitations. Namely, data cannot be verified for accuracy and may have inherent biases due to its retrospective nature. Additionally, NSQIP focuses on 30-day outcomes, limiting the ability to study the effects of CKD on long-term postoperative experiences or sequelae of chronically reduced renal function. Nonetheless, this study utilizes a substantially large, diverse cohort, allowing for generalizability to the larger population. Moreover, a wide range of outcomes were studied across surgical specialties, allowing for a comprehensive understanding of the effects of CKD on surgery. Additionally, we do not have information on perioperative anticoagulation or general DVT prophylaxis. Finally, there could still be unmeasured confounding that we failed to adjust, such as preoperative dialysis.

The findings of this study may be utilized to better approximate fitness for surgery and hence inform shared decision-making amongst providers and their patients. Namely, this study can inform the incorporation of CKD within novel risk stratification tools which predict the likelihood of specific adverse events following an operation. Identification of CKD in a patient undergoing surgery may also permit improved intraoperative and postoperative surveillance or prophylactic techniques to mitigate risk of specific complications.

Conclusions

In summary, this population-based study indicates the negative impacts of CKD on operative outcomes across a diverse range of procedures and patients. As CKD increases in prevalence, further research is necessary to better elucidate the effects of reduced renal function on surgical safety and patient experiences. An improved understanding of the multifactorial effects of CKD can facilitate shared decision-making and improve patient-centered outcomes across surgical specialties.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

None.

Author contributions

Conceptualization, C.R. and R.S.; Methodology, C.R.; Software, E.H. AND J.X.; Validation, E.H.; Formal analysis, M.G.; Writing—original draft preparation, C.R. and Y.B.S.; Writing—review and editing, Z.M., S.H., B.J.M, N.E., Z.K., A.J., C.J.D.W., and R.S.; Supervision, R.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data availability

The datasets generated and/or analysed during the current study are available in the American College of Surgeons National Surgical Quality Improvement Program repository. The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Declarations

Ethics approval and consent to participate

This study was deemed exempt by our institutional review board as the database used contains de-identified data.

Clinical trial number

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

GFR Glomerular filtration rate

CKD Chronic Kidney Disease

ACS-NSQIP American College of Surgeons National Surgical Quality Improvement Program

RECORD Reporting of Studies Conducted Using Observational Routinely Collected Health Data

CPT Common Procedural Terminology

ASA American Society of Anesthesiologists

BMI Body mass index

COPD Chronic obstructive pulmonary disease

SD Standard deviation

VTE Venous Thromboembolism

CI Confidence interval

DVT Deep venous thrombosis

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Levey AS Coresh J Tighiouart H Greene T Inker LA Measured and estimated glomerular filtration rate: current status and future directions Nat Rev Nephrol 2020 16 51 64 10.1038/s41581-019-0191-y 31527790
Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol. 2020;16:51–64. 10.1038/s41581-019-0191-y31527790 10.1038/s41581-019-0191-y
2. Stevens PE Levin A Kidney disease: improving global outcomes chronic kidney Disease Guideline Development Work Group, M. evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline Ann Intern Med 2013 158 825 30 10.7326/0003-4819-158-11-201306040-00007 23732715
Stevens PE, Levin A. Kidney disease: improving global outcomes chronic kidney Disease Guideline Development Work Group, M. evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30. 10.7326/0003-4819-158-11-201306040-0000723732715 10.7326/0003-4819-158-11-201306040-00007
3. Webster AC Nagler EV Morton RL Masson P Chronic kidney disease Lancet 2017 389 1238 52 10.1016/S0140-6736(16)32064-5 27887750
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238–52. 10.1016/S0140-6736(16)32064-527887750 10.1016/S0140-6736(16)32064-5
4. Fox CS Matsushita K Woodward M Bilo HJ Chalmers J Heerspink HJ Lee BJ Perkins RM Rossing P Sairenchi T Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis Lancet 2012 380 1662 73 10.1016/S0140-6736(12)61350-6 23013602
Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73. 10.1016/S0140-6736(12)61350-623013602 10.1016/S0140-6736(12)61350-6
5. Go AS Chertow GM Fan D McCulloch CE Hsu CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 2004 351 1296 305 10.1056/NEJMoa041031 15385656
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. 10.1056/NEJMoa04103115385656 10.1056/NEJMoa041031
6. Cloyd JM Ma Y Morton JM Kurella Tamura M Poultsides GA Visser BC Does chronic kidney disease affect outcomes after major abdominal surgery? Results from the National Surgical Quality Improvement Program J Gastrointest Surg 2014 18 605 12 10.1007/s11605-013-2390-3 24241964
Cloyd JM, Ma Y, Morton JM, Kurella Tamura M, Poultsides GA, Visser BC. Does chronic kidney disease affect outcomes after major abdominal surgery? Results from the National Surgical Quality Improvement Program. J Gastrointest Surg. 2014;18:605–12. 10.1007/s11605-013-2390-324241964 10.1007/s11605-013-2390-3
7. Karambelkar AD, Chawla LS, Busse LW. The perioperative management of the patient with chronic kidney disease. In Chronic Renal Disease; Elsevier: 2020; pp. 1291–1307.
8. Kozlowski L, Bielawska K, Zhymaila A, Malyszko J. Chronic kidney Disease Prevalence in patients with Colorectal Cancer undergoing surgery. Diagnostics (Basel). 2022;12. 10.3390/diagnostics12092137
9. Pizano A Scott CK Porras-Colon J Driessen AL Miller RT Timaran CH Modrall JG Tsai S Kirkwood ML Ramanan B Chronic kidney disease impacts outcomes after abdominal aortic aneurysm repair J Vasc Surg 2022 10.1016/j.jvs.2022.09.003 36400362
Pizano A, Scott CK, Porras-Colon J, Driessen AL, Miller RT, Timaran CH, Modrall JG, Tsai S, Kirkwood ML, Ramanan B. Chronic kidney disease impacts outcomes after abdominal aortic aneurysm repair. J Vasc Surg. 2022. 10.1016/j.jvs.2022.09.00336400362 10.1016/j.jvs.2022.09.003
10. Harrison TG Ruzycki SM James MT Ronksley PE Zarnke KB Tonelli M Manns BJ McCaughey D Schneider P Dixon E Estimated GFR and incidence of major surgery: a Population-based Cohort Study Am J Kidney Dis 2021 77 e361 365 75 10.1053/j.ajkd.2020.08.009 33039431
Harrison TG, Ruzycki SM, James MT, Ronksley PE, Zarnke KB, Tonelli M, Manns BJ, McCaughey D, Schneider P, Dixon E, et al. Estimated GFR and incidence of major surgery: a Population-based Cohort Study. Am J Kidney Dis. 2021;77(e361):365–75. 10.1053/j.ajkd.2020.08.00933039431 10.1053/j.ajkd.2020.08.009
11. Harrison TG Hemmelgarn BR James MT Manns BJ Tonelli M Brindle ME McCaughey D Ruzycki SM Zarnke KB Wick J Association of kidney function with Major postoperative events after non-cardiac ambulatory surgeries: a Population-based Cohort Study Ann Surg 2021 10.1097/SLA.0000000000005040 34475320
Harrison TG, Hemmelgarn BR, James MT, Manns BJ, Tonelli M, Brindle ME, McCaughey D, Ruzycki SM, Zarnke KB, Wick J, et al. Association of kidney function with Major postoperative events after non-cardiac ambulatory surgeries: a Population-based Cohort Study. Ann Surg. 2021. 10.1097/SLA.000000000000504034475320 10.1097/SLA.0000000000005040
12. American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). Frequently Asked Questions. Available online: https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/faq/ (accessed on February 13, 2022).
13. Benchimol EI Smeeth L Guttmann A Harron K Moher D Petersen I Sorensen HT von Elm E Langan SM Committee RW The REporting of studies conducted using Observational routinely-collected health data (RECORD) statement PLoS Med 2015 12 e1001885 10.1371/journal.pmed.1001885 26440803
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sorensen HT, von Elm E, Langan SM, Committee RW. The REporting of studies conducted using Observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12:e1001885. 10.1371/journal.pmed.100188526440803 10.1371/journal.pmed.1001885
14. von Elm E Altman DG Egger M Pocock SJ Gotzsche PC Vandenbroucke JP Initiative S The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Ann Intern Med 2007 147 573 7 10.7326/0003-4819-147-8-200710160-00010 17938396
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7. 10.7326/0003-4819-147-8-200710160-0001017938396 10.7326/0003-4819-147-8-200710160-00010
15. Wallis CJ Bjarnason G Byrne J Cheung DC Hoffman A Kulkarni GS Nathens AB Nam RK Satkunasivam R Morbidity and mortality of radical nephrectomy for patients with disseminated Cancer: an analysis of the National Surgical Quality Improvement Program Database Urology 2016 95 95 102 10.1016/j.urology.2016.04.055 27292566
Wallis CJ, Bjarnason G, Byrne J, Cheung DC, Hoffman A, Kulkarni GS, Nathens AB, Nam RK, Satkunasivam R. Morbidity and mortality of radical nephrectomy for patients with disseminated Cancer: an analysis of the National Surgical Quality Improvement Program Database. Urology. 2016;95:95–102. 10.1016/j.urology.2016.04.05527292566 10.1016/j.urology.2016.04.055
16. Inker LA Eneanya ND Coresh J Tighiouart H Wang D Sang Y Crews DC Doria A Estrella MM Froissart M New Creatinine- and cystatin C-Based equations to Estimate GFR without Race N Engl J Med 2021 385 1737 49 10.1056/NEJMoa2102953 34554658
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, et al. New Creatinine- and cystatin C-Based equations to Estimate GFR without Race. N Engl J Med. 2021;385:1737–49. 10.1056/NEJMoa210295334554658 10.1056/NEJMoa2102953
17. Delgado C Baweja M Crews DC Eneanya ND Gadegbeku CA Inker LA Mendu ML Miller WG Moxey-Mims MM Roberts GV A Unifying Approach for GFR Estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease Am J Kidney Dis 2022 79 e261 268 88 10.1053/j.ajkd.2021.08.003 34563581
Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, et al. A Unifying Approach for GFR Estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(e261):268–88. 10.1053/j.ajkd.2021.08.00334563581 10.1053/j.ajkd.2021.08.003
18. Weir CB, Jan ABMI. Classification Percentile And Cut Off Points. In StatPearls; Treasure Island (FL), 2022.
19. Carvalho Silveira F Martin WP Maranga G le Roux CW Ren-Fielding CJ The impact of CKD on Perioperative Risk and Mortality after bariatric surgery Kidney360 2021 2 236 44 10.34067/KID.0004832020 35373013
Carvalho Silveira F, Martin WP, Maranga G, le Roux CW, Ren-Fielding CJ. The impact of CKD on Perioperative Risk and Mortality after bariatric surgery. Kidney360. 2021;2:236–44. 10.34067/KID.000483202035373013 10.34067/KID.0004832020
20. Paajanen P Karkkainen JM Tenorio ER Mendes BC Oderich GS Effect of patient frailty status on outcomes of fenestrated-branched endovascular aortic repair for complex abdominal and thoracoabdominal aortic aneurysms J Vasc Surg 2022 76 e1172 1170 9 10.1016/j.jvs.2022.05.008 35697310
Paajanen P, Karkkainen JM, Tenorio ER, Mendes BC, Oderich GS. Effect of patient frailty status on outcomes of fenestrated-branched endovascular aortic repair for complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2022;76(e1172):1170–9. 10.1016/j.jvs.2022.05.00835697310 10.1016/j.jvs.2022.05.008
21. Atkins J Hess NR Fu S Read JM Hajj JM Ramu B Silverman DN Inampudi C Vanbakel AB Hashmi ZA Outcomes in patients with LVADs undergoing simultaneous heart-kidney transplantation J Card Fail 2022 28 1584 92 10.1016/j.cardfail.2022.04.016 35597511
Atkins J, Hess NR, Fu S, Read JM, Hajj JM, Ramu B, Silverman DN, Inampudi C, Vanbakel AB, Hashmi ZA, et al. Outcomes in patients with LVADs undergoing simultaneous heart-kidney transplantation. J Card Fail. 2022;28:1584–92. 10.1016/j.cardfail.2022.04.01635597511 10.1016/j.cardfail.2022.04.016
22. Qi Y He J Pan M Yan J Impact of impaired renal function on outcomes of chronic total occlusion undergoing revascularization: a systemic review and meta-analysis Int Urol Nephrol 2022 54 3179 91 10.1007/s11255-022-03192-7 35689780
Qi Y, He J, Pan M, Yan J. Impact of impaired renal function on outcomes of chronic total occlusion undergoing revascularization: a systemic review and meta-analysis. Int Urol Nephrol. 2022;54:3179–91. 10.1007/s11255-022-03192-735689780 10.1007/s11255-022-03192-7
23. Borrelli S Garofalo C Gabbai FB Liberti ME Chiodini P Simeon V De Nicola L Minutolo R Sex difference in cardiovascular risk in patients with chronic kidney disease: pooled analysis of four cohort studies Nephrol Dial Transpl 2023 10.1093/ndt/gfad036
Borrelli S, Garofalo C, Gabbai FB, Liberti ME, Chiodini P, Simeon V, De Nicola L, Minutolo R. Sex difference in cardiovascular risk in patients with chronic kidney disease: pooled analysis of four cohort studies. Nephrol Dial Transpl. 2023. 10.1093/ndt/gfad03610.1093/ndt/gfad036
24. Lacquaniti A, Campo S, Falliti G, Caruso D, Gargano R, Giunta E, Monardo P. Free light chains, high mobility Group Box 1, and Mortality in Hemodialysis patients. J Clin Med. 2022;11. 10.3390/jcm11236904
25. Adogwa O Elsamadicy AA Sergesketter A Oyeyemi D Galan D Vuong VD Khalid S Cheng J Bagley CA Karikari IO The impact of chronic kidney disease on postoperative outcomes in patients undergoing lumbar decompression and Fusion World Neurosurg 2018 110 e266 70 10.1016/j.wneu.2017.10.147 29109065
Adogwa O, Elsamadicy AA, Sergesketter A, Oyeyemi D, Galan D, Vuong VD, Khalid S, Cheng J, Bagley CA, Karikari IO. The impact of chronic kidney disease on postoperative outcomes in patients undergoing lumbar decompression and Fusion. World Neurosurg. 2018;110:e266–70. 10.1016/j.wneu.2017.10.14729109065 10.1016/j.wneu.2017.10.147
26. Hoggard TM Chen DQ Quinlan ND Bell JE Werner BC Cui Q Outcomes following total hip arthroplasty for osteonecrosis of the femoral head in patients on Hemodialysis J Bone Joint Surg Am 2022 104 90 4 10.2106/JBJS.20.00352 35389908
Hoggard TM, Chen DQ, Quinlan ND, Bell JE, Werner BC, Cui Q. Outcomes following total hip arthroplasty for osteonecrosis of the femoral head in patients on Hemodialysis. J Bone Joint Surg Am. 2022;104:90–4. 10.2106/JBJS.20.0035235389908 10.2106/JBJS.20.00352
27. Chen CT Lin SJ Kuo LT Chen TH Hsu WH Chen CL Yu PA Peng KT Tsai YH Effect of chronic kidney disease on outcomes following proximal humerus fragility fracture surgery in diabetic patients: a nationwide population-based cohort study PLoS ONE 2021 16 e0258393 10.1371/journal.pone.0258393 34624055
Chen CT, Lin SJ, Kuo LT, Chen TH, Hsu WH, Chen CL, Yu PA, Peng KT, Tsai YH. Effect of chronic kidney disease on outcomes following proximal humerus fragility fracture surgery in diabetic patients: a nationwide population-based cohort study. PLoS ONE. 2021;16:e0258393. 10.1371/journal.pone.025839334624055 10.1371/journal.pone.0258393
28. Ahn J Raspovic KM Liu GT Lavery LA La Fontaine J Nakonezny PA Wukich DK Renal function as a predictor of early transmetatarsal amputation failure Foot Ankle Spec 2019 12 439 51 10.1177/1938640018816371 30537872
Ahn J, Raspovic KM, Liu GT, Lavery LA, La Fontaine J, Nakonezny PA, Wukich DK. Renal function as a predictor of early transmetatarsal amputation failure. Foot Ankle Spec. 2019;12:439–51. 10.1177/193864001881637130537872 10.1177/1938640018816371
29. Ferrandino R Roof S Ma Y Chan L Poojary P Saha A Chauhan K Coca SG Nadkarni GN Teng MS Unplanned 30-Day readmissions after parathyroidectomy in patients with chronic kidney disease: a nationwide analysis Otolaryngol Head Neck Surg 2017 157 955 65 10.1177/0194599817721154 28949797
Ferrandino R, Roof S, Ma Y, Chan L, Poojary P, Saha A, Chauhan K, Coca SG, Nadkarni GN, Teng MS. Unplanned 30-Day readmissions after parathyroidectomy in patients with chronic kidney disease: a nationwide analysis. Otolaryngol Head Neck Surg. 2017;157:955–65. 10.1177/019459981772115428949797 10.1177/0194599817721154
30. Choudhary GR Jena R Likhiteswer P Gupta P Pandey H Yadav T Madduri VKS Singh M Patient REnal and Tumor Attribute score (PRETA score): a comprehensive renal nephrometry score for use in patients with renal masses planned for minimally invasive nephron sparing surgery J Robot Surg 2022 16 1463 70 10.1007/s11701-022-01389-7 35247165
Choudhary GR, Jena R, Likhiteswer P, Gupta P, Pandey H, Yadav T, Madduri VKS, Singh M. Patient REnal and Tumor Attribute score (PRETA score): a comprehensive renal nephrometry score for use in patients with renal masses planned for minimally invasive nephron sparing surgery. J Robot Surg. 2022;16:1463–70. 10.1007/s11701-022-01389-735247165 10.1007/s11701-022-01389-7
31. Nunns GR Moore EE Chapman MP Moore HB Stettler GR Peltz E Burlew CC Silliman CC Banerjee A Sauaia A The hypercoagulability paradox of chronic kidney disease: the role of fibrinogen Am J Surg 2017 214 1215 8 10.1016/j.amjsurg.2017.08.039 28951066
Nunns GR, Moore EE, Chapman MP, Moore HB, Stettler GR, Peltz E, Burlew CC, Silliman CC, Banerjee A, Sauaia A. The hypercoagulability paradox of chronic kidney disease: the role of fibrinogen. Am J Surg. 2017;214:1215–8. 10.1016/j.amjsurg.2017.08.03928951066 10.1016/j.amjsurg.2017.08.039
32. Parikh AM Spencer FA Lessard D Emery C Baylin A Linkletter C Goldberg RJ Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective Am J Kidney Dis 2011 58 746 55 10.1053/j.ajkd.2011.06.021 21872977
Parikh AM, Spencer FA, Lessard D, Emery C, Baylin A, Linkletter C, Goldberg RJ. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis. 2011;58:746–55. 10.1053/j.ajkd.2011.06.02121872977 10.1053/j.ajkd.2011.06.021
